Sheashaa, Hussein A.Ghoneim, Mohamed A.Sobh, Mohamed A.Ismail, Amani M.Rashad, Rashad H.Bakr, Mohamed A.2026-04-032011-08Experimental and Clinical Transplantation, Cilt, 9, Sayı, 4, 2011 ss. 247-2511304-0855https://hdl.handle.net/11727/14742Objectives: The effect of basiliximab induction therapy on long-term patient and graft survival is not clear. We sought to evaluate if there is any advantage to routine basiliximab induction on the long-term outcome of living-related donor kidney transplants. Materials and Methods: One hundred adult recipients with their first kidney allograft were randomized into 2 treatment groups; 1 group received basiliximab, and the second served as a control. All patients received a maintenance triple immunosuppressive therapy (steroids, cyclosporine, microemulsion, and azathioprine). We followed them for 10 years. Results: Basiliximab reduced the proportion of patients who experienced an acute rejection in the first year (18/50) when compared with the control group (31/50) (P = .009), and in 10 years (28/50) when compared with controls (37/50) (P = .059). The cumulative steroid dosage used throughout the study was significantly lower in the basiliximab group. The overall incidence of posttransplant complications was comparable among the 2 groups. There was no significant difference in patient and graft survival; 10-year patient and graft survival were 92% and 76% for basiliximab and 90% and 68% for the control group. Conclusions: Routine basiliximab induction significantly reduces the incidence of acute rejection without any noticeable effects on the long-term renal transplant outcome.enBasiliximabIL2 receptor antagonistsRenal transplantArticle942146-8427